Cardinal Health: Paying Up for Growth at a 1.3% Margin

Cardinal Health presents to investors today at Morgan Stanley's 24th Annual Global Healthcare Conference, and it does so from a place that makes most retail investors stop and squint: the stock has climbed about 53% over the past year and is now trading around $233, roughly 10% below its 52-week high. That is the setup that raises the only question that actually matters here — not "is it up a lot?" but "what am I paying for, and is it still worth paying for at this level?"

The answer depends almost entirely on who you line it up against, and there is one fair comparison: McKesson, its direct rival among the large U.S. drug distributors. Put the two side by side and the first thing that jumps out is a paradox.

Cheaper on sales, richer on earnings

Metric (trailing)	Cardinal Health (CAH)	McKesson (MCK)
Price / sales	0.21x	0.25x
EV / EBITDA	16.3x	14.9x
P/E (trailing)	31.7x	22.7x
Dividend yield	0.89%	0.39%

To read that: price/sales is how much you pay for every dollar of revenue, and EV/EBITDA is how much you pay for every dollar of operating profit. On a dollar of revenue, Cardinal is the cheaper stock. On a dollar of earnings — measured both ways — Cardinal is the richer one. Those two facts only coexist if one thing is true: Cardinal keeps far less profit out of each dollar of sales. And it does. Its trailing operating EBITDA margin sits around 1.3%. Cardinal is, in the purest sense, a low-margin middleman: it moves $254 billion of product through its warehouses each year and keeps a sliver of it.

So the market is not charging extra for the top line. What it is charging extra for is the direction those earnings are pointing.

The growth is real — and it has kept raising

The premium has a basis, and on the growth front the report card has been improving quarter over quarter. Fiscal 2026 revenue rose 14% to $254.2 billion. Non-GAAP earnings per share jumped 37% to $11.26. And management has just guided fiscal 2027 earnings to $12.40 to $12.60 — another 13% to 15% of growth, deliberately set above the company's own long-term target of 12% to 14%.

The engine is specialty pharmaceuticals, whose revenue grew more than 25% last year. This is not a single-quarter fluke. Watch how the full-year earnings forecast moved across 2026: it started near $9.65 to $9.85 in January, was raised after the second quarter, was raised again after the third, and the company then delivered $11.26. In our books, a number that keeps landing above the number you already updated is the most reliable signal in the stack — it means the street was consistently wrong in the company's favor, not that one lucky quarter got mislabeled.

One wobble in the cash

Here is the part the headline glosses over. A meaningful slice of that fiscal 2026 pop was a one-time windfall: refunds on tariffs the company had previously absorbed, worth about $100 million, or $0.31 per share. That single item accounts for roughly 15 of the 40 points of the fourth-quarter earnings gain — over a third of it. Strip it out and the full-year gain is still solid, up 33% to $10.95 — but the level of the beat was flattered.

The tell for the future is in the cash. Management guided fiscal 2027 free cash flow to $3.5 to $4.0 billion, down from $5.0 billion in fiscal 2026. That is not a business getting worse; it is the same refund not coming back. Management was explicit that the windfall will not repeat and that it is still paying to replace the tariffs. Meanwhile the underlying cash engine remains strong — the company has raised its dividend for 25 straight years (now a 0.89% yield) and bought back $1.4 billion of its own stock last year. The honest read is that the trend is strong and the level was temporarily inflated. Those are two different things, and the one that actually sets the valuation is the trend.

What it means for your portfolio

Put the factors together and you get a specific role, not a generic "healthcare holding." McKesson is the value lane — a lower multiple (14.9x EBITDA) on a structurally fatter margin, and the name you reach for when you want the distributor without paying up. Cardinal is the growth lane: you pay a premium multiple — 16.3x EBITDA and about 31x trailing earnings, a multiple that still sits well above the ~1.0 growth-adjusted line investors often use as a "cheap" threshold — for a much faster earnings climb, while accepting a 1.3% margin that leaves little cushion if drug pricing wobbles. AInvest's aggregate signal labels the stock a Buy, but note its middling fundamental sub-score: this premium is momentum- and growth-driven, not a pure fundamentals bargain.

So the discipline here is about the sleeve, not the price. A name up 53% with a premium multiple does not get trimmed just because it "looks rich" — hold is not sell, and the growth and the guidance above its own long-term target are still intact. What would genuinely change the read is a break in that specialty-pharma growth or a cut to the guidance, because that is the only thing justifying the earnings premium. Until one of those cracks, this belongs in the growth sleeve of a diversified portfolio, and the variable to watch is not today's conference call but whether that 25% specialty growth keeps compounding.